Reported Earlier, Apogee Therapeutics Prices Upsized $420M Underwritten Public Offering Of 6,774,193 Common Shares At $62/Share

 The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions.